Nyrada Receives Firm Commitments to Raise A$11 Million

Highlights:
• Firm commitments received to raise A$11 million with strong demand from existing and new investors
• Investment commitments from all Nyrada Directors over and above the A$11 million
• Proceeds to fund Phase 1 clinical trials in Cholesterol-Lowering and Brain Injury drug development programs
• Encouraging preclinical results from both programs and a new collaboration with Walter Reed and UNSW Sydney have strengthened Nyrada’s outlook
• Further preclinical results expected in the coming months, as the two lead programs advance towards the clinic by the end 2021 (Cholesterol-Lowering) and mid-2022 (Brain Injury)